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Abstract 41 
Background: Medications for opioid use disorder (MOUD) and alcohol use disorder (MAUD) are effective 42 
and under-prescribed. Hospital-based addiction consult services can engage out-of-treatment adults in 43 
addictions care. Understanding which patients are most likely to initiate MOUD and MAUD can inform 44 
interventions and deepen understanding of hospitals’ role addressing substance use disorders (SUD).  45 
 46 
Objective: Determine patient- and consult-service level characteristics associated with MOUD/MAUD 47 
initiation during hospitalization 48 
 49 
Methods: We analyzed data from a study of the Improving Addiction Care Team (IMPACT), an 50 
interprofessional hospital-based addiction consult service at an academic medical center. Researchers 51 
collected patient surveys and clinical data from September 2015 to May 2018. We used logistic 52 
regression to identify characteristics associated with medication initiation among participants with OUD, 53 
AUD, or both. Candidate variables included patient demographics, social determinants, and treatment-54 
related factors. 55 
 56 
Results: 339 participants had moderate to severe OUD, AUD, or both and were not engaged in 57 
MOUD/MAUD care at admission. Past methadone maintenance treatment (aOR 2.07, 95%CI (1.17, 58 
3.66)), homelessness (aOR 2.63, 95%CI (1.52, 4.53)), and partner substance use (aOR 2.05, 95%CI (1.12, 59 
3.76) were associated with MOUD/MAUD initiation. Concurrent methamphetamine use disorder (aOR 60 
0.32, 95%CI (0.18, 0.56)) was negatively associated with MOUD/MAUD initiation.  61 
Conclusions: The association of MOUD/MAUD initiation with homelessness and partner substance use 62 
suggests that hospitalization may be an opportunity to reach highly-vulnerable people, further 63 
underscoring the need to provide hospital-based addictions care as a health-system strategy. 64 
Methamphetamine’s negative association with MOUD/MAUD warrants further study. 65 
 66 
  67 
INTRODUCTION 68 
Hospitalization can be a reachable moment to initiate care for people with substance use disorders 69 
(SUD) (Englander et al., 2017). Many people with SUD who are admitted to general medical hospitals are 70 
not engaged in treatment and they do not come to the hospital seeking addictions care (Englander et al., 71 
2017; Velez et al., 2017). Hospitalization and acute illness can raise patients awareness of mortality and 72 
other harmful effects of substance use, and can be a strong motivation to initiate treatment (Velez et al., 73 
2017). Yet, little is known about who might benefit from hospital-based care. Understanding which 74 
patients are most likely to initiate MOUD and MAUD can inform interventions and deepen 75 
understanding of hospitals’ role addressing substance use disorders (SUD).  76 
 77 
Medications for opioid use disorder (MOUD) and alcohol use disorder (MAUD) are effective and under-78 
prescribed. Opioid agonist therapy (OAT) (methadone and buprenorphine) is first-line treatment for 79 
moderate to severe opioid use disorder. Decades of evidence show that OAT reduces overdose and all-80 
cause mortality by over half (Sordo et al., 2017), reduces risk of infectious disease transmission (Gowing 81 
et al., 2013; Tsui et al., 2014), and reduces criminal behavior associated with substance use (Rastegar et 82 
al., 2016). Further, hospitalization is a high-risk touchpoint after which people with opioid use disorder 83 
are at increased risk for overdose and death. A recent study in Massachusetts found that hospitalization 84 
for injection-related infection was associated with a 54-fold increase in mortality, and that MOUD can 85 
mitigate this risk (Larochelle et al., 2019). Medication, combined with psychosocial interventions, 86 
comprise first line treatment for moderate to severe alcohol use disorder. MAUD is associated with 87 
reduced drinking days, reduced alcohol consumption, and increased abstinence from alcohol (Jonas et 88 
al., 2014). Despite their effectiveness, less than 10% of people with alcohol use disorder receive MAUD 89 
(Substance Abuse and Mental Health Services Administration, 2017) and only 20%–40% of people with 90 
OUDs are receiving life-saving medication treatment (Jones et al., 2015). 91 
 92 
Nationally, hospital-based addiction medicine consult services are emerging as a way to engage out-of-93 
treatment adults in addictions care (Priest and McCarty, 2019). A study at a Boston academic medical 94 
center found that 30% of patients with high risk alcohol and drug use were engaged in treatment prior 95 
to admission, and that hospital addiction consultation was associated with increased treatment 96 
engagement after discharge (Wakeman et al., 2017). In a study of Oregon Medicaid recipients 97 
comparing adults seen by our addiction consult service to matched controls, we found that 17% of 98 
patients were engaged in treatment prior to hospitalization. Treatment engagement increased to 39% in 99 
the 34 days after discharge among patients seen by our addiction consult service, compared to 23% 100 
among matched-controls (Englander et al., 2019a). Healthcare Effectiveness Data and Information Set 101 
(HEDIS) identifies SUD treatment initiation and engagement as a national quality measure (National 102 
Committee for Quality Assurance, 2017), and hospitalization is an important part of the SUD care 103 
continuum.  104 
 105 
Little is known about which hospitalized patients are most likely to initiate MOUD and MAUD, and what 106 
consult service factors are associated with medication initiation. The goal of this study was to determine 107 
patient- and consult-service level characteristics associated with MOUD and MAUD initiation during 108 
hospitalization.  109 
 110 
METHODS 111 
Setting and study design: 112 
We analyzed survey data collected as part of a study of the Improving Addiction Care Team (IMPACT) at 113 
an urban, academic medical center in Portland, Oregon. IMPACT is a hospital-based addiction consult 114 
service that includes care from addiction medicine providers (physicians or advance-practice providers 115 
(APPs)), social workers, and peers with lived experience in recovery (Englander et al., 2017; Englander et 116 
al., 2019c). Inpatient medical and surgical providers, and hospital social workers refer patients with 117 
known or suspected SUD (excluding people with tobacco use disorders alone) to IMPACT, regardless of 118 
an individual’s readiness to change or interest in SUD treatment. In general, at least one member of 119 
IMPACT (MD/APP, SW, peer) visits patients daily during hospitalization, and peers often continue peer 120 
support 30-90 days after hospital discharge. Peers are often the first-line for patients who express low 121 
interest in treatment or working with IMPACT (Collins et al., 2019; Englander et al., 2019b). IMPACT 122 
performs an initial comprehensive assessment; elicits patient-centered goals; initiates SUD treatment, 123 
including pharmacotherapy and behavioral treatments; and offers harm reduction services. IMPACT can 124 
help manage acute pain and perioperative care, including MOUD/MAUD initiation in this population. 125 
IMPACT also includes robust referral pathways to post-hospital SUD care. IMPACT offers MOUD and 126 
MAUD to all patients with moderate-to-severe opioid and/or alcohol use disorder, and tailors 127 
medication decisions based on patient preferences, acute medical conditions, and post-hospital 128 
community treatment resources. For some patients, this includes coordinating treatment plans with 129 
skilled nursing facilities (e.g. coordinating take-out dosing from an opioid treatment program (OTP) or 130 
daily transportation to support patients to get methadone from an OTP while at SNF). The Oregon 131 
Health & Science University Institutional Review Board approved this study.  132 
 133 
Participants: 134 
Participants included patients seen by IMPACT and enrolled in the IMPACT evaluation between 135 
September 2015 and August 2018. Patients were eligible for this analysis if they 1) had moderate to 136 
severe opioid use disorder, alcohol use disorder, or both, and 2) were not already receiving MOUD or 137 
MAUD upon hospital admission. We operationalized the definition of current use of MOUD or MAUD by 138 
baseline questionnaire responses, which asked participants if they were currently receiving medication 139 
for opioid use disorder (e.g. methadone, buprenorphine, naltrexone), or medication for alcohol use 140 
disorder (e.g. acamprosate). 141 
Study procedures and data sources: 142 
Early in hospitalization, a trained research assistant who was not part of the clinical team administered 143 
an in-person survey. Surveys focused on demographics, substance use, and patient experience, and took 144 
approximately 15-20 minutes to complete. The research assistant collected patient surveys and directly 145 
entered responses into an online survey and database management system, REDCap, reviewing surveys 146 
afterwards for accuracy. At discharge, IMPACT clinical team members completed a case closure form 147 
during the daily team huddle. Case closure forms included information about a patient’s diagnoses, 148 
hospital course, and treatment plan. Trained research assistants validated information from case closure 149 
forms by chart review in the electronic health record, and then entered this information into REDCap. 150 
Finally, research team members abstracted data from electronic medical records.  151 
Measures: 152 
We selected potential covariates based on a priori hypotheses and face validity.  153 
Covariates from the patient survey included gender (male/female), race (American Indian/Alaska Native, 154 
Asian, African American/Black, Native Hawaiian/other Pacific Islander, white, more than one race, 155 
refused), income in the previous year ($10,000 increments, $0 to >$50,000), housing status 156 
(housed/unhoused), partner with substance use (yes/no), rural home zip code (yes/no), history of past 157 
but not current methadone maintenance engagement (yes/no) and access to a usual primary care clinic 158 
(yes/no). We identified rural zip codes using the Federal Office of Rural Health Policy designated rural zip 159 
codes (Health Resources & Services Administration, 2018). We determined past but not current 160 
methadone maintenance therapy using the Addiction Severity Index Lite (ASI-lite) measurement tool; 161 
and considered patients who identified past methadone maintenance therapy without use in the last 30 162 
days (Cacciola et al., 2007). Covariates from the case closure form included opioid use disorder (yes/no), 163 
alcohol use disorder (yes/no), methamphetamine use disorder (yes/no), peer support delivered in 164 
hospital (yes/no). Discussion with members of the clinical and research team suggested that cocaine and 165 
benzodiazepine use would be very low in our population; hence, we did not consider these covariates in 166 
our research. Covariates from chart review included patient age (years), insurance status (any Oregon 167 
Medicaid, Medicare, other), and number of IMPACT clinician and social worker visits per day 168 
(continuous).  169 
Our outcome measure was in-hospital initiation of MOUD, MAUD, or both, and was determined from 170 
case closure forms and validated via chart review. MOUD included the three FDA-approved medications 171 
for opioid use disorder: methadone, buprenorphine (including buprenorphine-naloxone), and 172 
naltrexone. MAUD included naltrexone, acamprosate, disulfiram, and gabapentin. We included 173 
gabapentin only if it was prescribed for treatment of alcohol use disorder. We elected to include 174 
gabapentin even though it is a not FDA approved for treatment of AUD because in hospitalized adults 175 
with AUD and acute pain on opioids who are reluctant to take multiple three-time daily medication, it 176 
can be the best alternative for MAUD. We felt including it was better reflective of MAUD initiation than 177 
excluding it. We excluded all medications if there was no plan to continue after hospital discharge; for 178 
example, methadone for withdrawal only with no plan for methadone maintenance post-discharge.  179 
Covariate manipulation 180 
We reclassified race as Caucasian/non-Caucasian because of sample size among non-Caucasian patients; 181 
we included patients who did not know their race, were missing race information or refused to answer 182 
as Caucasian. One participant was transgender; we reclassified this person the gender they identify with. 183 
If participants were unsure if they had any income in the previous year, we classified them as no income.  184 
Finally, we created a “dose indicator” for IMPACT delivery, defined as the total number of documented 185 
IMPACT provider or social worker encounters during hospitalization, divided by the total number of 186 
hospital days.  We dichotomized this as a binary covariate (at least 1 visit per day/less than 1 visit per 187 
day). We report this variable in our table but did not consider this for inclusion in our analyses, as it may 188 
be challenging to interpret without a measure of patient motivation for treatment and could represent 189 
confounding by indication.   190 
We were concerned that medication initiation would differ significantly by diagnosis (AUD, OUD or 191 
both). We chose to include an interaction term to determine if IMPACT delivery differed by diagnosis; if 192 
the interaction term was significant, we planned to present the terms separately in the paper.    193 
 194 
Data analysis 195 
Primary analysis and fit 196 
We built a logistic regression model to estimate the relationship of baseline participant characteristics 197 
with the binary outcome variable MOUD and/or MAUD initiation. We fit our logistic regression model 198 
using a conservative estimated covariate ratio of 10 events per degree of freedom (Cacciola et al., 2007). 199 
We used backwards stepwise elimination with a relaxed p-value of 0.20 to finalize our model and did not 200 
force any covariates into our model. We evaluated our continuous covariates for linearity in the log-201 
odds using Lowess scatter plot (comparing medication intention and continuous covariates individually 202 
and evaluated all covariates for collinearity using a correlation matrix). Finally, we used a Hosmer-203 
Lemeshow test to evaluate model goodness-of-fit (Hosmer and Lemeshow, 2000).  204 
For patients who were admitted more than once, we used only the first encounter to both comply with 205 
the assumption of independence in logistic regression testing and because we were primarily interested 206 
in associations with MOUD/MAUD initiation following a first encounter with IMPACT. We did not adjust 207 
for multiple comparisons in this exploratory study.  208 
Missing Data 209 
We anticipated minimal missingness in surveys conducted in the hospital, and so only included patients 210 
with complete covariate data, other than as listed in data manipulations above (Figure).  211 
Sensitivity analysis 212 
We conducted two sensitivity analyses. First, we identified influential observations using Pregibon’s 213 
Delta-Beta statistic. Observations with a Delta-Beta statistic greater than 0.20 were removed. Second, 214 
we re-ran our analyses without imputing Caucasian when race was missing. We planned to report 215 
results alongside the primary analysis if directionality or significance of any covariate changed.  216 
RESULTS 217 
During the study period, 760 patients were referred to IMPACT. Researchers approached 689 patients, 218 
and 486 consented to participate in surveying. Of those, 401 had moderate to severe OUD and/or AUD 219 
and 349 had no pharmacotherapy for OUD/AUD before admission (Figure). Two patients were identified 220 
as in “sustained remission” from both alcohol and opioid use and were excluded. One patient died in the 221 
hospital. 346 participants were eligible for inclusion in the model. Of those, 248 (71.7%) initiated 222 
MOUD/MAUD during hospitalization. Study participants were predominantly Caucasian (80.9%), had 223 
opioid use disorder without alcohol use disorder (52.0%), were experiencing homelessness (55.0%), had 224 
Medicaid insurance (76.3%), and had an established primary care clinic (61.3%). 30.0% of participants 225 
had a co-occurring moderate or severe methamphetamine use disorder (Table 1).    226 
In our analysis, past methadone maintenance treatment initiation (aOR 2.24, 95%CI (1.28, 3.94)), 227 
homelessness (aOR 2.52, 95%CI (1.47, 4.30)), and having a partner with substance use (aOR 2.06, 95%CI 228 
(1.13, 3.74were associated with MOUD/ MAUD initiation. Concurrent methamphetamine use disorder 229 
(aOR 0.32, 95%CI (0.18, 0.56)) was negatively associated with MOUD/MAUD initiation (Table 2). In 230 
addition to these covariates, backwards selection also included age and gender in our final model, 231 
though they are not statistically significant.  Neither sensitivity analysis changed the direction or 232 
significance of results. The interaction term evaluating if the IMPACT dose indicator varied by diagnosis 233 
(AUD only vs any OUD) was not significant, and was not included in the final model (p=0.97).  234 
Among participants with any OUD (n=219), methadone was the most common MOUD (n=80; 36.5%), 235 
followed by buprenorphine (n=62, 28.3%). Eight participants with OUD (3.7%) received intramuscular 236 
naltrexone. Among participants with any AUD (n=166), 41 (24.7%) received any naltrexone (oral or 237 
intramuscular), and 39 (23.5%) received acamprosate (Table 3). 238 
Discussion  239 
Our study identifies predictors of MOUD and/or MAUD initiation among hospitalized adults seen by an 240 
addiction consult service. We found that current homelessness or a partner with substance use 241 
predicted MOUD/MAUD initiation. Co-occurring methamphetamine use disorder, however, was 242 
negatively associated with MOUD/MAUD initiation. Residing in a rural area, having a usual source of 243 
primary care, and Medicaid insurance had no association with MOUD/MAUD initiation. To our 244 
knowledge, this is the first study describing patterns of MOUD/MAUD initiation among hospitalized 245 
adults seen by an addiction consult service. Our findings suggest ways in which hospital-based addiction 246 
care may differ from community treatment, and highlight how the reachable moment of hospitalization 247 
may differentially effect people with co-occurring methamphetamine use, those experiencing 248 
homelessness or those with a partner with substance use.  249 
This research builds on existing research in several important ways. The finding that 74% of people with 250 
moderate to severe OUD and/or AUD initiated medication supports earlier work showing that 251 
hospitalization can be a reachable moment and opportunity engage non-treatment seeking adults by 252 
interrupting drug use and serving as a “wakeup call” (Velez et al., 2017). Though this study was not 253 
designed to examine post-hospital treatment engagement, our findings are contextualized and 254 
promising in light of earlier work showing that hospital-initiated addictions care is associated with 255 
increased treatment engagement after discharge (Englander et al., 2019a).  256 
This study highlights ways in which hospitalization may present a unique opportunity to initiate care. 257 
Notably, most research in community settings suggests that homelessness is associated with lower 258 
MOUD/MAUD initiation and engagement (Appel et al., 2004; Prangnell et al., 2016; Damian et al., 2017; 259 
Lo et al., 2018; Watkins et al., 2018), and some studies find no association (Simon et al., 2017; Tsui et al., 260 
2018). Previous studies in community settings found that having a partner with substance use is 261 
associated with lower readiness to engage in treatment (Riehman et al., 2000).  By contrast, our study 262 
found increased rates of MOUD/MAUD initiation in this population. Though we do not have data to 263 
explain this unexpected finding, we speculate that there may be an important interplay between 264 
motivation to initiate treatment and barriers to care. Specifically, patients with fewer barriers who are 265 
motivated to initiate treatment may do so prior to hospitalization. Our findings suggest that 266 
hospitalization may serve as an opportunity to engage hard-to-reach populations.  267 
The finding that co-occurring methamphetamine use disorder is negatively associated with MOUD/ 268 
MAUD initiation is important. Methamphetamine hospitalizations are surging (Winkelman et al., 2018) 269 
and methamphetamine use is an emerging public health issue, with an estimated 250% increase in 270 
stimulant-related deaths nationally from January 2015 to October 2018 (Ahmad et al., 2019). In Oregon, 271 
rates appear even worse, with a 400% increase in deaths related to methamphetamines between 2010 272 
and 2018 (Oregon-Idaho HIDTA Program, 2019). 273 
Little is known about the association of methamphetamine use and treatment with medications for 274 
opioid and alcohol use in general, and specifically among hospitalized adults. However, our research is 275 
consistent with earlier work in community settings. One study of clients with opioid and 276 
methamphetamine use who accessed services across 17 Washington State syringe exchanges found that 277 
recent methamphetamine use was negatively associated with interest in getting help for OUD 278 
(AOR = 0.49; 95% CI: 0.26, 0.91) (Frost et al., 2018). Another primary care based study among people 279 
with OUD and recent stimulant use found that clinic policies eliminating the requirement for stimulant 280 
abstinence were associated with higher rates of buprenorphine initiation, but also with lower 281 
buprenorphine treatment retention (Payne et al., 2019).  282 
The negative association of methamphetamine use with MOUD/MAUD initiation warrants further 283 
exploration, and could be due to a variety of system-, provider-, or patient-factors. We speculate that 284 
patients with methamphetamine use may perceive their alcohol and/or opioid use as secondary and not 285 
needing MOUD/MAUD or that methamphetamine withdrawal, cravings, or psychiatric symptoms may 286 
interfere with patients or providers’ ability to initiate MOUD/MAUD. It is also possible that community 287 
SUD treatment policies influence patients’ decisions about MOUD/MAUD, as methadone and 288 
buprenorphine treatment programs commonly dismiss patients if their urine drug screens result positive 289 
for methamphetamine. Though unknown, it is also possible that methamphetamine use is a marker for 290 
social marginalization or other factors that might make people less likely to initiate MOUD/MAUD. Co-291 
use of methamphetamines and opioids is increasingly common due to synergistic euphoric or balancing 292 
effects; easier access to methamphetamine; social pressures to co-use; and co-use as a marker for more 293 
severe SUD (Ellis et al., 2018). How these factors effect non-treatment seeking, hospitalized adults 294 
remains unclear.   295 
This study has several limitations. It is a single-site study and all patients received care from an addiction 296 
consult service. Findings may not be transferable to settings without a consult service or where the 297 
consult service is comprised of different team members or has different activities. Second, not all 298 
IMPACT patients agreed to participate in the survey. It is possible that people who participated were 299 
more or less likely to initiate MOUD/MAUD. Further, this study took place in Oregon and participants 300 
had low racial and ethnic diversity. Additionally, we asked patients about past methadone use because 301 
this is included in the ASI-lite, but we did not ask about other past MOUD or MAUD exposure. 302 
Associations between all types of past MOUD/MAUD treatment may be important to test in predicting 303 
hospital MOUD/MAUD in future studies. Further, our analysis not adjust for multiple comparisons as the 304 
nature of this work was exploratory. Additionally, we looked only at the association of MOUD/MAUD 305 
initiation following a first encounter with IMPACT. Future research should explore effects of repeated 306 
exposure to addiction consult services for individuals who are readmitted to hospitals and have repeat 307 
addiction consultation. Future studies should also explore additional patient- and consult-service factors 308 
that promote MOUD/MAUD initiation such as patient readiness to change. This analysis included all 309 
participants regardless of AMA discharge. Our hypothesis is that AMA discharge would be strongly 310 
predictive of not initiating MOUD/MAUD with a plan to continue; future studies could explore this more 311 
closely. Finally, while important, medication initiation does not reflect long-term treatment 312 
engagement. Future studies of treatment engagement and retention specific to MOUD/MAUD will be 313 
important. 314 
 315 
Our study has several important implications for clinical care and research. First, the findings that 316 
homelessness and having a partner with substance use was positively associated with MOUD/MAUD 317 
initiation suggests that these vulnerable people may not be accessing treatment outside of the hospital. 318 
It also supports the potential value of an interprofessional hospital-based addictions team with 319 
resources dedicated to addressing social factors that may influence treatment retention after discharge. 320 
For IMPACT, this includes social workers and peers who work to connect people with housing, engage 321 
partners in addictions care, develop relapse prevention plans, and tailor post hospital treatment plans to 322 
support retention in care. Our findings also have implications for community treatment, highlighting the 323 
importance of addressing social determinants of health across the continuum of hospital and 324 
community SUD to support treatment engagement and retention.  325 
The fact that methamphetamine use is associated with lower MOUD/MAUD initiation is important, 326 
especially as we consider drivers for the opioid overdose crisis. Most opioid overdose deaths involve 327 
multiple substances (Barocas et al., 2019) and initiation of MOUD during acute care encounters is critical 328 
to overdose prevention (Larochelle et al., 2018). Our findings suggest the need for further research to 329 
explore the association of methamphetamine use and MOUD, MAUD, and hospital-based addiction 330 
medicine care. Future studies should also examine effect of MOUD/MAUD initiation during 331 
hospitalization on pertinent clinical outcomes including substance use, long-term SUD treatment 332 
engagement, healthcare utilization, quality of life, overdose risks, and other health outcomes. 333 
  334 
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